Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Emend
EMEND 125 mg hard capsules EMEND 80 mg hard capsules · Abschnitt 4.5 · PDF-Seite 5
HOS-112512 · Präparat HOS-093697
Corticosteroids
Dexamethasone: The usual oral dexamethasone dose should be reduced by approximately 50 % when
co-administered with EMEND 125 mg/80 mg regimen. The dose of dexamethasone in chemotherapy
induced nausea and vomiting (CINV) clinical trials was chosen to account for active substance
interactions (see section 4.2). EMEND, when given as a regimen of 125 mg with dexamethasone
co-administered orally as 20 mg on Day 1, and EMEND when given as 80 mg/day with
dexamethasone co-administered orally as 8 mg on Days 2 through 5, increased the AUC of
dexamethasone, a CYP3A4 substrate, 2.2-fold on Days 1 and 5.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dexamethasone (HOS-084535)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-24T11:24:00Z · SHA-256 afd6062a51e59b36e448c9117685894e4529fcde2f5e673f4401f91bb32d7081 · Passage afe01c9dab2d5ed350a4f668b414792517b030eaded46e6d82e9e8c2ec6f31d6 · Zeichen 1618–2233 im Abschnitt
Wechselwirkungen · Emend
EMEND 125 mg hard capsules EMEND 80 mg hard capsules · Abschnitt 4.5 · PDF-Seite 6
HOS-112523 · Präparat HOS-093697
In a third study with intravenous and oral administration of midazolam, EMEND was given as 125 mg
on Day 1 and 80 mg/day on Days 2 and 3, together with ondansetron 32 mg Day 1, dexamethasone
12 mg Day 1 and 8 mg Days 2-4. This combination (i.e. EMEND, ondansetron and dexamethasone)
decreased the AUC of oral midazolam 16 % on Day 6, 9 % on Day 8, 7 % on Day 15 and 17 % on
Day 22. These effects were not considered clinically important.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dexamethasone (HOS-084535) ondansetron (HOS-086052) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-24T11:24:00Z · SHA-256 afd6062a51e59b36e448c9117685894e4529fcde2f5e673f4401f91bb32d7081 · Passage e89a86f9bd9675653582dd455df89b4d981dfbcf92b2b749485aef8ad34dc053 · Zeichen 5532–5969 im Abschnitt
Wechselwirkungen · Emend
EMEND 125 mg hard capsules EMEND 80 mg hard capsules · Abschnitt 4.5 · PDF-Seite 7
HOS-112530 · Präparat HOS-093697
In a clinical study, single doses of an oral contraceptive containing ethinyl estradiol and norethindrone
were administered on Days 1 through 21 with EMEND, given as a regimen of 125 mg on Day 8 and
80 mg/day on Days 9 and 10 with ondansetron 32 mg intravenously on Day 8 and oral dexamethasone
given as 12 mg on Day 8 and 8 mg/day on Days 9, 10, and 11. During days 9 through 21 in this study,
there was as much as a 64 % decrease in ethinyl estradiol trough concentrations and as much as a 60 %
decrease in norethindrone trough concentrations.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ethinyl estradiol (HOS-088135) dexamethasone (HOS-084535) norethindrone (HOS-088136) ondansetron (HOS-086052)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-24T11:24:00Z · SHA-256 afd6062a51e59b36e448c9117685894e4529fcde2f5e673f4401f91bb32d7081 · Passage 456a53ee821cf7117e27fd75824a728559405134b74c86f503237f1ada5cf674 · Zeichen 8547–9092 im Abschnitt
Wechselwirkungen · Emend
EMEND 125 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 22
HOS-112573 · Präparat HOS-093697
Corticosteroids
Dexamethasone: The usual oral dexamethasone dose should be reduced by approximately 50 % when
co-administered with EMEND 125 mg/80 mg regimen. The dose of dexamethasone in chemotherapy
induced nausea and vomiting (CINV) clinical trials was chosen to account for active substance
interactions (see section 4.2). EMEND, when given as a regimen of 125 mg with dexamethasone
co-administered orally as 20 mg on Day 1, and EMEND when given as 80 mg/day with
dexamethasone co-administered orally as 8 mg on Days 2 through 5, increased the AUC of
dexamethasone, a CYP3A4 substrate, 2.2-fold on Days 1 and 5.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dexamethasone (HOS-084535)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-24T11:24:00Z · SHA-256 afd6062a51e59b36e448c9117685894e4529fcde2f5e673f4401f91bb32d7081 · Passage afe01c9dab2d5ed350a4f668b414792517b030eaded46e6d82e9e8c2ec6f31d6 · Zeichen 1562–2177 im Abschnitt
Wechselwirkungen · Emend
EMEND 125 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 23
HOS-112582 · Präparat HOS-093697
In a third study with intravenous and oral administration of midazolam, EMEND was given as 125 mg
on Day 1 and 80 mg/day on Days 2 and 3, together with ondansetron 32 mg Day 1, dexamethasone
12 mg Day 1 and 8 mg Days 2-4. This combination (i.e. EMEND, ondansetron and dexamethasone)
decreased the AUC of oral midazolam 16 % on Day 6, 9 % on Day 8, 7 % on Day 15 and 17 % on
Day 22. These effects were not considered clinically important.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dexamethasone (HOS-084535) ondansetron (HOS-086052) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-24T11:24:00Z · SHA-256 afd6062a51e59b36e448c9117685894e4529fcde2f5e673f4401f91bb32d7081 · Passage e89a86f9bd9675653582dd455df89b4d981dfbcf92b2b749485aef8ad34dc053 · Zeichen 5477–5914 im Abschnitt
Wechselwirkungen · Emend
EMEND 125 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 24
HOS-112589 · Präparat HOS-093697
In a clinical study, single doses of an oral contraceptive containing ethinyl estradiol and norethindrone
were administered on Days 1 through 21 with EMEND, given as a regimen of 125 mg on Day 8 and
80 mg/day on Days 9 and 10 with ondansetron 32 mg intravenously on Day 8 and oral dexamethasone
given as 12 mg on Day 8 and 8 mg/day on Days 9, 10, and 11. During days 9 through 21 in this study,
there was as much as a 64 % decrease in ethinyl estradiol trough concentrations and as much as a 60 %
decrease in norethindrone trough concentrations.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ethinyl estradiol (HOS-088135) dexamethasone (HOS-084535) norethindrone (HOS-088136) ondansetron (HOS-086052)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-24T11:24:00Z · SHA-256 afd6062a51e59b36e448c9117685894e4529fcde2f5e673f4401f91bb32d7081 · Passage 456a53ee821cf7117e27fd75824a728559405134b74c86f503237f1ada5cf674 · Zeichen 8491–9036 im Abschnitt
Wechselwirkungen · Velcade
VELCADE 1 mg powder for solution for injection · Abschnitt 4.5 · PDF-Seite 12
HOS-112771 · Präparat HOS-093755
In the same drug-drug interaction study assessing the effect of dexamethasone, a weaker CYP3A4
inducer, on the pharmacokinetics of bortezomib (injected intravenously), there was no significant
effect on the pharmacokinetics of bortezomib based on data from 7 patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dexamethasone (HOS-084535)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-18T11:00:00Z · SHA-256 0614ac01c21d9bc8ee31aa893ca113f39ffb5c8e9d9927b551be4a1d9803dc15 · Passage 119dd0cbce1bab5d6e93f29525aa16852360491606aaf2bac376b045fa1a7977 · Zeichen 1422–1690 im Abschnitt
Wechselwirkungen · Velcade
VELCADE 3.5 mg powder for solution for injection · Abschnitt 4.5 · PDF-Seite 44
HOS-112804 · Präparat HOS-093755
In the same drug-drug interaction study assessing the effect of dexamethasone, a weaker CYP3A4
inducer, on the pharmacokinetics of bortezomib (injected intravenously), there was no significant
effect on the pharmacokinetics of bortezomib based on data from 7 patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dexamethasone (HOS-084535)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-18T11:00:00Z · SHA-256 0614ac01c21d9bc8ee31aa893ca113f39ffb5c8e9d9927b551be4a1d9803dc15 · Passage 119dd0cbce1bab5d6e93f29525aa16852360491606aaf2bac376b045fa1a7977 · Zeichen 1476–1744 im Abschnitt
Wechselwirkungen · Aloxi
Aloxi 250 micrograms solution for injection. · Abschnitt 4.5 · PDF-Seite 4
HOS-113198 · Präparat HOS-093879
CYP2D6 inducers and inhibitors
In a population pharmacokinetic analysis, it has been shown that there was no significant effect on
palonosetron clearance when co-administered with CYP2D6 inducers (dexamethasone and
rifampicin) and inhibitors (including amiodarone, celecoxib, chlorpromazine, cimetidine, doxorubicin,
fluoxetine, haloperidol, paroxetine, quinidine, ranitidine, ritonavir, sertraline or terbinafine).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): paroxetine (HOS-086246) celecoxib (HOS-113199) cimetidine (HOS-085835) terbinafine (HOS-113069) quinidine (HOS-085593) chlorpromazine (HOS-087796) dexamethasone (HOS-084535) sertraline (HOS-086247) fluoxetine (HOS-085946) ranitidine (HOS-085660) haloperidol (HOS-085602) ritonavir (HOS-084521) amiodarone (HOS-085596) doxorubicin (HOS-084538)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2018-07-19T02:00:00Z · SHA-256 294736e442282815f621d4f12b360c42aed3d38df16efb8bd8e9ff8f6ed0cae7 · Passage 405ce1b5c93dcb69a231a7ada6748b256dfcf0a71d2419c40d11e3d2fd5c9701 · Zeichen 677–1092 im Abschnitt
Wechselwirkungen · Aloxi
Aloxi 500 micrograms soft capsules · Abschnitt 4.5 · PDF-Seite 18
HOS-113220 · Präparat HOS-093879
In a population pharmacokinetic analysis, it has been shown that there was no significant effect on
palonosetron clearance when co-administered with CYP2D6 inducers (dexamethasone and
rifampicin) and inhibitors (including amiodarone, celecoxib, chlorpromazine, cimetidine, doxorubicin,
fluoxetine, haloperidol, paroxetine, quinidine, ranitidine, ritonavir, sertraline or terbinafine).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): paroxetine (HOS-086246) celecoxib (HOS-113199) cimetidine (HOS-085835) terbinafine (HOS-113069) quinidine (HOS-085593) chlorpromazine (HOS-087796) dexamethasone (HOS-084535) sertraline (HOS-086247) fluoxetine (HOS-085946) ranitidine (HOS-085660) haloperidol (HOS-085602) ritonavir (HOS-084521) amiodarone (HOS-085596) doxorubicin (HOS-084538)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2018-07-19T02:00:00Z · SHA-256 294736e442282815f621d4f12b360c42aed3d38df16efb8bd8e9ff8f6ed0cae7 · Passage 0191c7188a7e27628b782f7d5521cff360102fd7edb892e6828ae21469ac42ea · Zeichen 888–1272 im Abschnitt
Wechselwirkungen · Sutent
Sutent 12.5 mg hard capsules Sutent 25 mg hard capsules Sutent 37.5 mg hard capsules Sutent 50 mg hard capsules · Abschnitt 4.5 · PDF-Seite 9
HOS-115666 · Präparat HOS-094337
Administration of sunitinib with potent CYP3A4 inducers (e.g., dexamethasone, phenytoin,
carbamazepine, rifampicin, phenobarbital or herbal preparations containing St. John’s
Wort/Hypericum perforatum) may decrease sunitinib concentrations. Combination with
CYP3A4 inducers should therefore be avoided, or selection of an alternate concomitant medicinal
product, with no or minimal potential to induce CYP3A4 should be considered. If this is not possible,
the dose of Sutent may need to be increased in 12.5 mg increments (up to 87.5 mg per day for GIST
and MRCC or 62.5 mg per day for pNET), based on careful monitoring of tolerability (see
section 4.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) dexamethasone (HOS-084535) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-10T16:28:00Z · SHA-256 d4826c56622b44e469b640c130fb21e1e289d4b954183f420d9e8d3bf8379fe6 · Passage 030bfba86823307c120c4aeabd4d4d93306a033ae424a82c9348d363b39b7072 · Zeichen 1700–2355 im Abschnitt
Wechselwirkungen · Nexavar
Nexavar 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-115748 · Präparat HOS-094353
Administration of rifampicin for 5 days before administration of a single dose of sorafenib resulted in
an average 37 % reduction of sorafenib AUC. Other inducers of CYP3A4 activity and/or
glucuronidation (e.g. Hypericum perforatum also known as St. John’s wort, phenytoin,
carbamazepine, phenobarbital, and dexamethasone) may also increase metabolism of sorafenib and
thus decrease sorafenib concentrations.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) dexamethasone (HOS-084535) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-28T11:40:00Z · SHA-256 4561f7f7d54908430c2d44ab3a6a7808fbf136793e601e405c6fd3f8791d1b27 · Passage 07295c2600b0c3648cb73411b91b9babeda7df54a591e61fa546808958667469 · Zeichen 31–439 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 19–20
HOS-116394 · Präparat HOS-094447
19
ANTIPSYCHOTICS/NEUROLEPTICS
Quetiapine Not studied. Boosted PREZISTA is Concomitant administration of
expected to increase these antipsychotic boosted PREZISTA and quetiapine
plasma concentrations. is contraindicated as it may
(CYP3A inhibition) increase quetiapine-related
toxicity. Increased concentrations
of quetiapine may lead to coma
(see section 4.3).
Perphenazine Not studied. Boosted PREZISTA is A dose decrease may be needed for
Risperidone expected to increase these antipsychotic these drugs when co-administered
Thioridazine plasma concentrations. with boosted PREZISTA.
(CYP3A, CYP2D6 and/or P-gp
Lurasidone inhibition) Concomitant administration of
Pimozide boosted PREZISTA and
Sertindole lurasidone, pimozide or sertindole
is contraindicated (see section 4.3).
β-BLOCKERS
Carvedilol Not studied. Boosted PREZISTA is Clinical monitoring is
Metoprolol expected to increase these β-blocker recommended when
Timolol plasma concentrations. co-administering boosted
(CYP2D6 inhibition) PREZISTA with β-blockers. A
lower dose of the β-blocker should
be considered.
CALCIUM CHANNEL BLOCKERS
Amlodipine Not studied. Boosted PREZISTA can be Clinical monitoring of therapeutic
Diltiazem expected to increase the plasma and adverse effects is
Felodipine concentrations of calcium channel recommended when these
Nicardipine blockers. medicines are concomitantly
Nifedipine (CYP3A and/or CYP2D6 inhibition) administered with boosted
Verapamil PREZISTA.
CORTICOSTEROIDS
Corticosteroids primarily Fluticasone: in a clinical study where Concomitant use of boosted
metabolised by CYP3A ritonavir 100 mg capsules twice daily PREZISTA and corticosteroids (all
(including were co-administered with 50 g routes of administration) that are
betamethasone, intranasal fluticasone propionate (4 times metabolised by CYP3A may
budesonide, fluticasone, daily) for 7 days in healthy subjects, increase the risk of development of
mometasone, prednisone, fluticasone propionate plasma systemic corticosteroid effects,
triamcinolone) concentrations increased significantly, including Cushing’s syndrome and
whereas the intrinsic cortisol levels adrenal suppression.
decreased by approximately 86% (90%
CI 82-89%). Greater effects may be Co-administration with CYP3A-
expected when fluticasone is inhaled. metabolised corticosteroids is not
Systemic corticosteroid effects including recommended unless the potential
Cushing’s syndrome and adrenal benefit to the patient outweighs the
suppression have been reported in risk, in which case patients should
patients receiving ritonavir and inhaled or be monitored for systemic
intranasally administered fluticasone. The corticosteroid effects.
effects of high fluticasone systemic
exposure on ritonavir plasma levels are Alternative corticosteroids which
unknown. are less dependent on CYP3A
metabolism e.g. beclomethasone
Other corticosteroids: interaction not should be considered, particularly
studied. Plasma concentrations of these for long term use.
medicinal products may be increased
when co-administered with boosted
PREZISTA, resulting in reduced serum
cortisol concentrations.
Dexamethasone Not studied. Dexamethasone may Systemic dexamethasone should
(systemic) decrease plasma concentrations of be used with caution when
darunavir. combined with boosted
(CYP3A induction) PREZISTA.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) quetiapine (HOS-086150) diltiazem (HOS-086288) triamcinolone (HOS-086333) nifedipine (HOS-086289) fluticasone (HOS-108914) nicardipine (HOS-090619) felodipine (HOS-108908) fluticasone propionate (HOS-086331) carvedilol (HOS-115322) risperidone (HOS-086280) amlodipine (HOS-086287) thioridazine (HOS-086281) perphenazine (HOS-116395) calcium (HOS-085615) betamethasone (HOS-090066) dexamethasone (HOS-084535) lead (HOS-085592) budesonide (HOS-086332) pimozide (HOS-085600) mometasone (HOS-114048) ritonavir (HOS-084521) beclomethasone (HOS-086334) lurasidone (HOS-086148) prednisone (HOS-084526) metoprolol (HOS-090094) timolol (HOS-090571) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 06bb26e6737c57cc3c74485aceb2076b3feb5ff5bad566ac99081f05e0924029 · Zeichen 52002–57572 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 61–62
HOS-116527 · Präparat HOS-094447
61
Perphenazine Not studied. PREZISTA is expected to A dose decrease may be needed for
Risperidone increase these antipsychotic plasma these drugs when co-administered
Thioridazine concentrations. with PREZISTA co-administered
(CYP3A, CYP2D6 and/or P-gp with low dose ritonavir.
inhibition)
Lurasidone Concomitant administration of
Pimozide PREZISTA with low dose
Sertindole ritonavir and lurasidone, pimozide
or sertindole is contraindicated
(see section 4.3).
β-BLOCKERS
Carvedilol Not studied. PREZISTA is expected to Clinical monitoring is
Metoprolol increase these β-blocker plasma recommended when
Timolol concentrations. co-administering PREZISTA with
(CYP2D6 inhibition) β-blockers. A lower dose of the
β-blocker should be considered.
CALCIUM CHANNEL BLOCKERS
Amlodipine Not studied. PREZISTA co-administered Clinical monitoring of therapeutic
Diltiazem with low dose ritonavir can be expected and adverse effects is
Felodipine to increase the plasma concentrations of recommended when these
Nicardipine calcium channel blockers. medicines are concomitantly
Nifedipine (CYP3A and/or CYP2D6 inhibition) administered with PREZISTA with
Verapamil low dose ritonavir.
CORTICOSTEROIDS
Corticosteroids primarily Fluticasone: in a clinical study where Concomitant use of PREZISTA
metabolised by CYP3A ritonavir 100 mg capsules twice daily with low dose ritonavir and
(including were co-administered with 50 g corticosteroids (all routes of
betamethasone, intranasal fluticasone propionate (4 times administration) that are
budesonide, fluticasone, daily) for 7 days in healthy subjects, metabolised by CYP3A may
mometasone, prednisone, fluticasone propionate plasma increase the risk of development of
triamcinolone) concentrations increased significantly, systemic corticosteroid effects,
whereas the intrinsic cortisol levels including Cushing’s syndrome and
decreased by approximately 86% (90% adrenal suppression.
CI 82-89%). Greater effects may be
expected when fluticasone is inhaled. Co-administration with CYP3A-
Systemic corticosteroid effects including metabolised corticosteroids is not
Cushing’s syndrome and adrenal recommended unless the potential
suppression have been reported in benefit to the patient outweighs the
patients receiving ritonavir and inhaled or risk, in which case patients should
intranasally administered fluticasone. The be monitored for systemic
effects of high fluticasone systemic corticosteroid effects.
exposure on ritonavir plasma levels are
unknown. Alternative corticosteroids which
are less dependent on CYP3A
Other corticosteroids: interaction not metabolism e.g. beclomethasone
studied. Plasma concentrations of these should be considered, particularly
medicinal products may be increased for long term use.
when co-administered with PREZISTA
with low dose ritonavir, resulting in
reduced serum cortisol concentrations.
Dexamethasone Not studied. Dexamethasone may Systemic dexamethasone should
(systemic) decrease plasma concentrations of be used with caution when
darunavir. combined with PREZISTA
(CYP3A induction) co-administered with low dose
ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) diltiazem (HOS-086288) triamcinolone (HOS-086333) nifedipine (HOS-086289) fluticasone (HOS-108914) nicardipine (HOS-090619) felodipine (HOS-108908) fluticasone propionate (HOS-086331) carvedilol (HOS-115322) risperidone (HOS-086280) amlodipine (HOS-086287) thioridazine (HOS-086281) perphenazine (HOS-116395) calcium (HOS-085615) betamethasone (HOS-090066) dexamethasone (HOS-084535) budesonide (HOS-086332) pimozide (HOS-085600) mometasone (HOS-114048) ritonavir (HOS-084521) beclomethasone (HOS-086334) lurasidone (HOS-086148) prednisone (HOS-084526) metoprolol (HOS-090094) timolol (HOS-090571) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 8b9ea54ec289adeef1a2f9f81165d44d84f0b8d5433cec6f77b7df8c89fd8286 · Zeichen 43290–48378 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 101–102
HOS-116617 · Präparat HOS-094447
101
ANTIPSYCHOTICS/NEUROLEPTICS
Quetiapine Not studied. Boosted PREZISTA is Concomitant administration of
expected to increase these antipsychotic boosted PREZISTA and quetiapine
plasma concentrations. is contraindicated as it may
(CYP3A inhibition) increase quetiapine-related
toxicity. Increased concentrations
of quetiapine may lead to coma
(see section 4.3).
Perphenazine Not studied. Boosted PREZISTA is A dose decrease may be needed for
Risperidone expected to increase these antipsychotic these drugs when co-administered
Thioridazine plasma concentrations. with boosted PREZISTA.
(CYP3A, CYP2D6 and/or P-gp
Lurasidone inhibition) Concomitant administration of
Pimozide boosted PREZISTA and
Sertindole lurasidone, pimozide or sertindole
is contraindicated (see section 4.3).
β-BLOCKERS
Carvedilol Not studied. Boosted PREZISTA is Clinical monitoring is
Metoprolol expected to increase these β-blocker recommended when
Timolol plasma concentrations. co-administering boosted
(CYP2D6 inhibition) PREZISTA with β-blockers. A
lower dose of the β-blocker should
be considered.
CALCIUM CHANNEL BLOCKERS
Amlodipine Not studied. Boosted PREZISTA can be Clinical monitoring of therapeutic
Diltiazem expected to increase the plasma and adverse effects is
Felodipine concentrations of calcium channel recommended when these
Nicardipine blockers. medicines are concomitantly
Nifedipine (CYP3A and/or CYP2D6 inhibition) administered with boosted
Verapamil PREZISTA.
CORTICOSTEROIDS
Corticosteroids primarily Fluticasone: in a clinical study where Concomitant use of boosted
metabolised by CYP3A ritonavir 100 mg capsules twice daily PREZISTA and corticosteroids (all
(including were co-administered with 50 g routes of administration) that are
betamethasone, intranasal fluticasone propionate (4 times metabolised by CYP3A may
budesonide, fluticasone, daily) for 7 days in healthy subjects, increase the risk of development of
mometasone, prednisone, fluticasone propionate plasma systemic corticosteroid effects,
triamcinolone) concentrations increased significantly, including Cushing’s syndrome and
whereas the intrinsic cortisol levels adrenal suppression.
decreased by approximately 86% (90%
CI 82-89%). Greater effects may be Co-administration with CYP3A-
expected when fluticasone is inhaled. metabolised corticosteroids is not
Systemic corticosteroid effects including recommended unless the potential
Cushing’s syndrome and adrenal benefit to the patient outweighs the
suppression have been reported in risk, in which case patients should
patients receiving ritonavir and inhaled or be monitored for systemic
intranasally administered fluticasone. The corticosteroid effects.
effects of high fluticasone systemic
exposure on ritonavir plasma levels are Alternative corticosteroids which
unknown. are less dependent on CYP3A
metabolism e.g. beclomethasone
Other corticosteroids: interaction not should be considered, particularly
studied. Plasma concentrations of these for long term use.
medicinal products may be increased
when co-administered with boosted
PREZISTA, resulting in reduced serum
cortisol concentrations.
Dexamethasone Not studied. Dexamethasone may Systemic dexamethasone should
(systemic) decrease plasma concentrations of be used with caution when
darunavir. combined with boosted
(CYP3A induction) PREZISTA.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) quetiapine (HOS-086150) diltiazem (HOS-086288) triamcinolone (HOS-086333) nifedipine (HOS-086289) fluticasone (HOS-108914) nicardipine (HOS-090619) felodipine (HOS-108908) fluticasone propionate (HOS-086331) carvedilol (HOS-115322) risperidone (HOS-086280) amlodipine (HOS-086287) thioridazine (HOS-086281) perphenazine (HOS-116395) calcium (HOS-085615) betamethasone (HOS-090066) dexamethasone (HOS-084535) lead (HOS-085592) budesonide (HOS-086332) pimozide (HOS-085600) mometasone (HOS-114048) ritonavir (HOS-084521) beclomethasone (HOS-086334) lurasidone (HOS-086148) prednisone (HOS-084526) metoprolol (HOS-090094) timolol (HOS-090571) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage ccb6e0bf9fbd4db134b19a5c68f5c32c6656fffa35e00c9b9b966f86c2226743 · Zeichen 51473–57044 im Abschnitt
Wechselwirkungen · Sprycel
SPRYCEL 20 mg film-coated tablets SPRYCEL 50 mg film-coated tablets SPRYCEL 70 mg film-coated tablets SPRYCEL 80 mg film-coated tablets SPRYCEL 100 mg film-coated tablets SPRYCEL 140 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11
HOS-116684 · Präparat HOS-094467
Active substances that may decrease dasatinib plasma concentrations
When dasatinib was administered following 8 daily evening administrations of 600 mg rifampicin, a
potent CYP3A4 inducer, the AUC of dasatinib was decreased by 82%. Other medicinal products that
induce CYP3A4 activity (e.g. dexamethasone, phenytoin, carbamazepine, phenobarbital or herbal
preparations containing Hypericum perforatum, also known as St. John´s Wort) may also increase
metabolism and decrease dasatinib plasma concentrations. Therefore, concomitant use of potent
CYP3A4 inducers with dasatinib is not recommended. In patients in whom rifampicin or other
CYP3A4 inducers are indicated, alternative medicinal products with less enzyme induction potential
should be used. Concomitant use of dexamethasone, a weak CYP3A4 inducer, with dasatinib is
allowed; dasatinib AUC is predicted to decrease approximately 25% with concomitant use of
dexamethasone, which is not likely to be clinically meaningful.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) dexamethasone (HOS-084535) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-02T12:05:00Z · SHA-256 c065657005bf3f51d58db1cb5b29a1453d36e1fc897c0adb5e47ed684f07722e · Passage b9d9a781ab26bd8e2947e41f1a0cf7ec84e800b5e37d5e0e8075592d440724e0 · Zeichen 828–1807 im Abschnitt
Wechselwirkungen · Sprycel
SPRYCEL 10 mg/mL powder for oral suspension · Abschnitt 4.5 · PDF-Seite 47
HOS-116738 · Präparat HOS-094467
Active substances that may decrease dasatinib plasma concentrations
When dasatinib was administered following 8 daily evening administrations of 600 mg rifampicin, a
potent CYP3A4 inducer, the AUC of dasatinib was decreased by 82%. Other medicinal products that
induce CYP3A4 activity (e.g. dexamethasone, phenytoin, carbamazepine, phenobarbital or herbal
preparations containing Hypericum perforatum, also known as St. John´s Wort) may also increase
metabolism and decrease dasatinib plasma concentrations. Therefore, concomitant use of potent
CYP3A4 inducers with dasatinib is not recommended. In patients in whom rifampicin or other
CYP3A4 inducers are indicated, alternative medicinal products with less enzyme induction potential
should be used. Concomitant use of dexamethasone, a weak CYP3A4 inducer, with dasatinib is
allowed; dasatinib AUC is predicted to decrease approximately 25% with concomitant use of
dexamethasone, which is not likely to be clinically meaningful.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) dexamethasone (HOS-084535) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-02T12:05:00Z · SHA-256 c065657005bf3f51d58db1cb5b29a1453d36e1fc897c0adb5e47ed684f07722e · Passage b9d9a781ab26bd8e2947e41f1a0cf7ec84e800b5e37d5e0e8075592d440724e0 · Zeichen 828–1807 im Abschnitt
Wechselwirkungen · Revlimid
Revlimid 2.5 mg hard capsules Revlimid 5 mg hard capsules Revlimid 7.5 mg hard capsules Revlimid 10 mg hard capsules Revlimid 15 mg hard capsules Revlimid 20 mg hard capsules Revlimid 25 mg hard capsules · Abschnitt 4.5 · PDF-Seite 24
HOS-117071 · Präparat HOS-094537
Erythropoietic agents, or other agents that may increase the risk of thrombosis, such as hormone replacement
therapy, should be used with caution in multiple myeloma patients receiving lenalidomide with
dexamethasone (see sections 4.4 and 4.8).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dexamethasone (HOS-084535)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-09T12:08:00Z · SHA-256 0f6cca94a1a136a03ce79918070d9d16a6919ff303eae396136f3a6bdce58c5c · Passage 0e36de6aa7ebe4e5fb4488142018ae051817083b5687067f8fc2a29c48597f73 · Zeichen 0–244 im Abschnitt
Wechselwirkungen · Revlimid
Revlimid 2.5 mg hard capsules Revlimid 5 mg hard capsules Revlimid 7.5 mg hard capsules Revlimid 10 mg hard capsules Revlimid 15 mg hard capsules Revlimid 20 mg hard capsules Revlimid 25 mg hard capsules · Abschnitt 4.5 · PDF-Seite 24
HOS-117072 · Präparat HOS-094537
Oral contraceptives
No interaction study has been performed with oral contraceptives. Lenalidomide is not an enzyme inducer. In
an in vitro study with human hepatocytes, lenalidomide, at various concentrations tested did not induce
CYP1A2, CYP2B6, CYP2C9, CYP2C19 and CYP3A4/5. Therefore, induction leading to reduced efficacy of
medicinal products, including hormonal contraceptives, is not expected if lenalidomide is administered
alone. However, dexamethasone is known to be a weak to moderate inducer of CYP3A4 and is likely to also
affect other enzymes as well as transporters. It may not be excluded that the efficacy of oral contraceptives
may be reduced during treatment. Effective measures to avoid pregnancy must be taken (see sections 4.4 and
4.6).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dexamethasone (HOS-084535)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-09T12:08:00Z · SHA-256 0f6cca94a1a136a03ce79918070d9d16a6919ff303eae396136f3a6bdce58c5c · Passage c88d799e45450766b9cfa94518ac9b8d2bccc81f3ca48e48b20b519f3f688e08 · Zeichen 246–1005 im Abschnitt
Wechselwirkungen · Revlimid
Revlimid 2.5 mg hard capsules Revlimid 5 mg hard capsules Revlimid 7.5 mg hard capsules Revlimid 10 mg hard capsules Revlimid 15 mg hard capsules Revlimid 20 mg hard capsules Revlimid 25 mg hard capsules · Abschnitt 4.5 · PDF-Seite 24
HOS-117073 · Präparat HOS-094537
Warfarin
Co-administration of multiple 10 mg doses of lenalidomide had no effect on the single dose
pharmacokinetics of R- and S- warfarin. Co-administration of a single 25 mg dose of warfarin had no effect
on the pharmacokinetics of lenalidomide. However, it is not known whether there is an interaction during
clinical use (concomitant treatment with dexamethasone). Dexamethasone is a weak to moderate enzyme
inducer and its effect on warfarin is unknown. Close monitoring of warfarin concentration is advised during
the treatment.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dexamethasone (HOS-084535) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-09T12:08:00Z · SHA-256 0f6cca94a1a136a03ce79918070d9d16a6919ff303eae396136f3a6bdce58c5c · Passage a97f4d8828c28442d97fb3e6b0b0e59bf969c4a0e5ee3842cf1ef35e842e0ef2 · Zeichen 1007–1541 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.